{"product_id":"golidocitinib","title":"Golidocitinib","description":"\u003cp\u003eGolidocitinib  \u003cspan class=\"xn-money\"\u003e(DZD4205) \u003c\/span\u003eis currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r\/r PTCL. In \u003cspan class=\"xn-chron\"\u003eJune 2024\u003c\/span\u003e, golidocitinib was approved by the National Medical Products Administration (NMPA) of \u003cspan class=\"xn-location\"\u003eChina\u003c\/span\u003e for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r\/r PTCL).\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eGolidocitinib \u003c\/span\u003esold under the brand name 高瑞哲® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e《\u003ca href=\"https:\/\/www.prnewswire.com\/news-releases\/golidocitinib-approved-in-china-as-first-in-class-jak1-only-inhibitor-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma-302176781.html\"\u003eGolidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma\u003c\/a\u003e》\u003c\/p\u003e","brand":"Dizal Pharma, China","offers":[{"title":"Default Title","offer_id":44797956587563,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-3054.png?v=1787022264","url":"https:\/\/xomeds.com\/products\/golidocitinib","provider":"XOMEDS","version":"1.0","type":"link"}